Oncology Conference update  

Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Prof. Nicolas Girard

Prof. Nicolas Girard
Publication Date

Mar 2026

info Summary and next episodes
Video

We're excited to announce that Prof. Nicolas Girard will be joining us at the European Lung Cancer Congress, ELCC 2026, to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

 

We anticipate that Prof. Girard may review data from the following studies: 

 

  • Beamion LUNG-1: Zongertinib in treatment-naȉve patients with HER2-mutant NSCLC, including those with active brain metastases. Heymach J, et al. Abstract 6MO, ELCC 2026

 

  • SOHO-01: Characterisation and management of sevabertinib-induced diarrhea. Girard N, et al. Abstract 18P, ELCC 2026

 

  • OptiTROP-Lung03: Sacituzumab tirumotecan in patients with previously treated advanced EGFR-mutated NSCLC: Final OS analysis from the randomised study. Yang Y, et al. Abstract LBA4, ELCC 2026

 

  • Clinical outcomes in patients with early-stage HER2-mutated NSCLC: A prospective cohort study. Gros L, et al. Abstract 239P, ELCC 2026

 

 

Come back soon to watch his short summary video, get the key clinical takeaways, and download the accompanying slides for a more detailed update.

 

Click here to sign up to the email list and be the first to know when this update is released.

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2 directed NSCLC 

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Prof. Nicolas Girard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research grants/support from Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen,  Leo Pharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi and Sivan.

Consultative services for Abbvie,  Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen  Hoffmann-La Roche, Janssen, Leo Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer,  Pierre Fabre, Sanofi and Takeda.

Participation on a data safety monitoring board for Hoffmann-La Roche.

Employment of a family member with AstraZeneca.
Slides

We're excited to announce that Prof. Nicolas Girard will be joining us at the European Lung Cancer Congress, ELCC 2026, to share his views on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at the congress. 

 

We anticipate that Prof. Girard may review data from the following studies: 

 

  • Beamion LUNG-1: Zongertinib in treatment-naȉve patients with HER2-mutant NSCLC, including those with active brain metastases. Heymach J, et al. Abstract 6MO, ELCC 2026

 

  • SOHO-01: Characterisation and management of sevabertinib-induced diarrhea. Girard N, et al. Abstract 18P, ELCC 2026

 

  • OptiTROP-Lung03: Sacituzumab tirumotecan in patients with previously treated advanced EGFR-mutated NSCLC: Final OS analysis from the randomised study. Yang Y, et al. Abstract LBA4, ELCC 2026

 

  • Clinical outcomes in patients with early-stage HER2-mutated NSCLC: A prospective cohort study. Gros L, et al. Abstract 239P, ELCC 2026

 

 

Come back soon to watch his short summary video, get the key clinical takeaways, and download the accompanying slides for a more detailed update.

 

Click here to sign up to the email list and be the first to know when this update is released.

  • Understand the clinical trial data and emerging profiles of therapies for the treatment of molecularly driven lung cancer, including treatments for HER2 directed NSCLC 

Nicolas Girard is a pneumologist specialising in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. 

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. 

He is Professor of Respiratory Medicine at Versailles Saint Quentin University, Paris Saclay Campus. He is the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Departement at Institut Curie in Paris.

Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.

Prof. Nicolas Girard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research grants/support from Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen,  Leo Pharma, Lilly, Merk Serono, Merck Sharp & Dohme, Novartis, Sanofi and Sivan.

Consultative services for Abbvie,  Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen  Hoffmann-La Roche, Janssen, Leo Pharma, Lilly, Merck Sharp & Dohme, Mirati, Novartis, Pfizer,  Pierre Fabre, Sanofi and Takeda.

Participation on a data safety monitoring board for Hoffmann-La Roche.

Employment of a family member with AstraZeneca.
Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Other episodes of this series
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

 Current Episode
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
Exon20group ISLB
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved
Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Other episodes of this series
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

 Current Episode
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
Exon20group ISLB
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved
Programme summary
  • clock Duration 1 MIN
  • clock Language(s) flag
Other episodes of this series
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

 Current Episode
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
Endorsement
ICAN international cancer advocacy network Biomarker Collaborative
Exon20group ISLB
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
Explore all programmes